Health
Chronicle Pharmabiz
Telangana DCA busts unlicensed medical device unit in Sangareddy
IN a major enforcement action, the DCA of Telangana busted an unlicensed medical device manufacturing facility in Sangareddy District on December 23, 2025.
1 min |
January 1, 2026
Chronicle Pharmabiz
Motilal Oswal invests US$ 72 mn in Sensa Core
MOTILAL Oswal Alternates had Monde Oswal AlternatES made a significant minority investment of US$ 72 million in Sensa Core, an innovation-driven medical devices' company focused on advancing healthcare technology in India.
1 min |
January 1, 2026
Chronicle Pharmabiz
Odisha announces Pharma, Med Devices Policy 2025
MARKING a historic shift in the state's industrial landscape, chief minister Mohan Charan Majhi has officially unveiled the Odisha Pharmaceutical and Medical Devices Policy 2025 at the inaugural Odisha Pharma Summit in Bhubaneswar on December 16.
1 min |
January 1, 2026
Chronicle Pharmabiz
Experts highlight policy intervention in pricing reforms
PRICING reforms must balance affordability with industry viability. Rational, transparent pricing models, volume-forprice contracts, and tiered pricing for non-essential therapies can sustain manufacturer participation going forward, highlights Dr Kunal Saxena, managing director, Rusan Pharma Ltd.
1 min |
January 1, 2026
Chronicle Pharmabiz
Glenmark launches epinephrine in US market
GLENMARK PharmaceutiGcals Inc, USA (Glenmark) Glenannounced the launch of epinephrine injection USP, 30 mg/30 mL (1 mg/mL) multiple-dose vial.
1 min |
January 1, 2026
Chronicle Pharmabiz
SSSIHMS, Siemens Healthineers ink research pact
SHRI Sathya Sai Institute of Higher Medical Sciences (SSSIHMS) and Siemens Healthineers have entered a strategic clinical research collaboration titled, 'Collaborative Clinical Research in Echocardiography.'
1 min |
January 1, 2026
Chronicle Pharmabiz
PCI to continue as a high-level professional standard setting body
Following the landmark decision to retain the Pharmacy Council of India's (PCI) independent status under the Viksit Bharat Shiksha Adhishthan (VBSA) Bill, 2025, the legislation unveils a sophisticated new architecture for the profession.
1 min |
January 1, 2026
Chronicle Pharmabiz
Pondicherry refers multi-crore counterfeit medicine racket to CBI
As the Government of Pondicherry has officially handed over the massive counterfeit medicine scandal to the Central Bureau of Investigation (CBI) and the National Investigation Agency (NIA), the focus of the probe is shifting from the initial arrests to a series of alarming, unanswered questions.
1 min |
January 1, 2026
Chronicle Pharmabiz
AFDLHF announces boycott of MMGPA tender
THE All Food and Drug Licence Holders Foundation (AFDLHF) has announced a complete boycott of the Maharashtra Medical Goods Authority (MMGPA) tender process, citing serious concerns over the introduction of an unlawful and anti-competitive \"Bunch Bid\" clause impacting Pharma Micro, Small and Medium Enterprises (MSMEs).
1 min |
January 1, 2026
Chronicle Pharmabiz
Daiichi Sankyo & AstraZeneca's Enhertu approved in China
ENHERTU (trastuzumab deruxtecan) has been approved China for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer that has progressed on one or more endocrine therapies in the metastatic setting.
1 min |
January 1, 2026
Chronicle Pharmabiz
Sanofi to acquire Dynavax Technologies
SANOFI announced that it has entered into an agreement to acquire Dynavax Technologies Corporation (Dynavax), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (Heplisav-B) and differentiated shingles vaccine candidate.
1 min |
January 1, 2026
Chronicle Pharmabiz
TN PTA merges with TNCDA as veteran leaders return
In consolidation of the pharmaceutical trade in Tamil Nadu, the Tamil Nadu Chemists and Druggists Association (TNCDA) has announced the merger of the breakaway Tamil Nadu Pharmaceutical Traders Association (TNPTA) back into its fold.
2 min |
January 1, 2026
Chronicle Pharmabiz
CDSCO reports 205 samples as NSQ in November
EVEN as almost 18 states and five Union Territories (UTs) did not submit the Not of Standard Quality (NSQ) drug samples data, the Central Drugs Standard Control Organisation (CDSCO) has reported 205 samples of NSQs during the month of November, 2025.
2 min |
January 1, 2026
Chronicle Pharmabiz
VBSA Bill 2025 proposes formal repeal of AICTE Act to end dual-regulatory hurdles
IN a decisive move to eliminate decades of administrative ambiguity, the Viksit Bharat Shiksha Adhishthan (VBSA) Bill 2025 has proposed the formal repeal of the All India Council for Technical Education (AICTE) Act, 1987.
1 min |
January 1, 2026
Chronicle Pharmabiz
DoP extends time till Jan 16 to submit applications under PLI Scheme
THE DoP has extended the timeline for the industry to submit their applications for support under the Production Linked Incentive (PLI) Scheme for bulk drugs to produce key ingredients of broad-spectrum carbapenem antibiotic meropenem and antiretroviral drug ritonavir.
1 min |
January 1, 2026
Chronicle Pharmabiz
"AI-powered screening a gamechanger to prevent blindness"
INDIA's eye healthcare is entering into a transformative phase with artificial intelligence (AI) and advanced data analysis.
2 min |
January 1, 2026
Chronicle Pharmabiz
NPPA to allow SII to quit producing 2 pack sizes of TT vaccine
THE National Pharmaceutical Pricing Authority (NPPA) has decided to allow Pune-based Serum Institute of India (SII) to discontinue the production and sale of two pack sizes of its tetanus toxoid injection, after finding that the market share of the drug has been negligible in the recent years and there are other products available in the market.
3 min |
January 1, 2026
Chronicle Pharmabiz
Doctors issue advisory urging action on air pollution health crisis
IN an unprecedented collective appeal, more than eighty Padma Awardee doctors from across India have issued a joint national advisory stating that India has been battling severe air pollution for over a decade, with its health impact now reaching an unmanageable scale.
2 min |
January 1, 2026
Chronicle Pharmabiz
Great Learning launches AD in healthcare programme
GREAT Learning, a leading global edtech company, has launched the AI in healthcare programme in collaboration with Johns Hopkins University (JHU), a globally top-ranked university in medicine and public health. .
1 min |
January 1, 2026
Chronicle Pharmabiz
Resolution Committee of IPC urges Centre to implement 4 key reforms
THE Resolution Committee of the 74th edition of the Indian Pharmaceutical Congress (IPC) has urged the Union government to implement four key reforms aimed at strengthening and future-proofing the pharmaceutical sector.
1 min |
January 1, 2026
Chronicle Pharmabiz
Omeros' Yartemlea gets US FDA approval
OMEROS Corporation, an innovative biotechnology company, announced that the US Food and Drug Administration (FDA) has approved Yartemlea (narsoplimabwuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement.
1 min |
January 1, 2026
Chronicle Pharmabiz
Reuse of SUDs takes centre stage at Medicine & Law Convention 2025
THE 10th National Conven2025 spotlights reuse of singleuse devices to balance cost and patient safety.
2 min |
January 1, 2026
Chronicle Pharmabiz
'Australian health advisory on counterfeit Abhavrab is over-cautionary, misplaced'
HYDERABAD-based Indian Lim Immunologicals ited (IIL), one of the largest producers of vaccines in Asia, has refuted the recent advisory from the Australian health advisory related to counterfeit rabies vaccine batches reported in India, stating that the advisory does not reflect the current situation.
2 min |
January 1, 2026
Chronicle Pharmabiz
Wegovy pill approved in US as first oral GLP-1 for weight mgmt
Novo Nordisk has announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.
2 min |
January 1, 2026
Chronicle Pharmabiz
Odisha envisages global pharma leadership via uncapped fiscal incentives
THE recently launched Odisha Pharmaceutical & Medical Devices Policy 2025 envisages a dramatic reduction in the financial barriers to entry, positioning the state as India's most cost-effective destination for healthcare manufacturing.
2 min |
January 1, 2026
Chronicle Pharmabiz
NIT Rourkela bags SPARC project for research
NATIONAL Institute of Technology Rourkela (NIT Rourkela) has been awarded a research project valued at Rs. 95.16 lakh for research on wearable robotic devices: Exoskeletons.
1 min |
January 1, 2026
Chronicle Pharmabiz
Ajanta Pharma and Biocon to market semaglutide in 26 countries
AJANTA Pharma Ltd., a specialty pharmaceutical formulation company, announced that it has entered into an in-licensing agreement with Biocon Ltd. for semaglutide, a GLP-1 receptor agonist.
2 min |
January 1, 2026
Chronicle Pharmabiz
BD Biosciences opens CoE for single-cell multiomics
BD Life Sciences, a segment of BD (Becton, Dickinson and Company), a global leader in life sciences, in collaboration with the Council of Scientific & Industrial Research (CSIR) - Institute of Genomics and Integrative Biology (IGIB), has announced the inauguration of its first Centre of Excellence (CoE) for Single-Cell Multiomics in India.
1 min |
January 1, 2026
Chronicle Pharmabiz
Panel asks MoA to fill up vacant posts in autonomous bodies
THE Parliamentary Panel on Health and Family Welfare has asked the Ministry of Ayush (MoA) to assess the vacant positions in various autonomous bodies and research councils and take a centralised course of action to fill up the estimated over 2,600 posts at an accelerated pace.
2 min |
January 1, 2026
Chronicle Pharmabiz
'Ayur institutions can play key role to boost Swasth Bharat Vision'
UNION minister of state for the ministry of Ayush and health and family welfare of India, Prataprao Ganpatrao Jadhav, stated that ancient ayurvedic institutions like Arya Vaidya Sala, Kottakkal, will play a key role in strengthening the vision of Swasth Bharat.
2 min |